Prospective Comparison of ¹⁸F-Fluorometh ⁶⁸Ga-PSMA PET/CT in Prostate Cancer Pat Curative Treatment and Are Being Considered for Targe

Journal of Nuclear Medicine

56, 1185-1190

DOI: 10.2967/jnumed.115.160382

Citation Report

#	Article	IF	Citations
1	18F-Fluoride PET in the Assessment of Malignant Bone Disease. Journal of Nuclear Medicine, 2015, 56, 1476-1477.	2.8	3
2	PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics, 2015, 5, 1388-1401.	4.6	186
3	Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Research, 2015, 5, 66.	1.1	118
4	Updates of prostate cancer staging: Prostate-specific membrane antigen. Investigative and Clinical Urology, 2016, 57, S147.	1.0	6
5	Contemporary Management of Prostate Cancer. F1000Research, 2016, 5, 179.	0.8	9
6	Usefulness of Ga-68 HBED-CC PSMA PET/CT for Tumor Staging in the Initial Diagnostic Assessment of Prostate Cancer. Journal of Nuclear Medicine & Radiation Therapy, 2016, 7, .	0.2	2
7	Targeted Therapy for Metastatic Prostate Cancer with Radionuclides. , 2016, , .		5
8	Metabolic Imaging in Prostate Cancer: Where We Are. Frontiers in Oncology, 2016, 6, 225.	1.3	21
9	⁶⁸Ga-HBED-CC-PSMA PET/CT Versus Histopathology In Primary Localized Prostate Cancer: A Voxel-Wise Comparison. Theranostics, 2016, 6, 1619-1628.	4.6	89
10	Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617. Clinical Nuclear Medicine, 2016, 41, 572-573.	0.7	13
11	68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clinical Nuclear Medicine, 2016, 41, 515-521.	0.7	165
12	Prostate-specific membrane antigen positron emission tomography in prostate cancer. Current Opinion in Oncology, 2016, 28, 216-221.	1.1	45
13	PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e549-e552.	0.9	19
14	A pilot study of the utility of choline <scp>PET</scp>â€“<scp>CT</scp> in prostate cancer biochemical relapse following radical prostatectomy. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 374-381.	0.9	1
15	Have we overcome choline PET/CT for early detection of prostate cancer recurrence?. Nuclear Medicine Communications, 2016, 37, 567-569.	0.5	1
16	⁶⁸Gaâ€PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU International, 2016, 117, 732-739.	1.3	239
17	68Ga-Labeled Antiâ€“Prostate-Specific Membrane Antigen Peptide as Marker for Androgen Deprivation Therapy Response in Prostate Cancer. Clinical Nuclear Medicine, 2016, 41, 423-425.	0.7	10
18	Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Research, 2016, 6, 78.	1.1	78

#	Article	IF	Citations
19	Evidence-based indications for the use of PET-CT in the United Kingdom 2016. Clinical Radiology, 2016, 71, e171-e188.	0.5	62
20	PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Molecular Imaging and Biology, 2016, 18, 411-419.	1.3	202
21	The Current Status of PSMA PET-CT for Evaluating Biochemical PSA Relapse in Prostate Cancer. Current Radiology Reports, 2016, 4, 1.	0.4	0
22	32nd International Austrian Winter Symposium. EJNMMI Research, 2016, 6, 32.	1.1	0
23	Multi-technique hybrid imaging in PET/CT and PET/MR: what does the future hold?. Clinical Radiology, 2016, 71, 660-672.	0.5	16
24	PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer and Prostatic Diseases, 2016, 19, 223-230.	2.0	121
25	The promise of multiparametric imaging in oncology: how do we move forward?. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1195-1198.	3.3	7
26	PSMA PET and Radionuclide Therapy in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 522-535.	2.5	82
28	Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1177-1188.	1.5	38
29	What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 6S-12S.	2.8	12
30	Prostate-Specific Membrane Antigenâ€“Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 90S-96S.	2.8	48
31	The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 79S-89S.	2.8	200
32	Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. Future Oncology, 2016, 12, 2393-2396.	1.1	3
33	Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. Clinical and Translational Imaging, 2016, 4, 439-447.	1.1	56
34	PET imaging of recurrent and metastatic prostate cancer with novel tracers. Future Oncology, 2016, 12, 2463-2477.	1.1	11
35	The oncologistsâ€™ unmet clinical needs for imaging in advanced prostate cancer. Clinical and Translational Imaging, 2016, 4, 423-431.	1.1	2
36	Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 405-418.	2.5	72
37	Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer. Nuclear Medicine and Biology, 2016, 43, 692-720.	0.3	66

#	Article	IF	Citations
38	The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. British Journal of Pharmacology, 2016, 173, 3041-3079.	2.7	71
39	Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2122-2130.	3.3	42
40	Update on advances in molecular PET in urological oncology. Japanese Journal of Radiology, 2016, 34, 470-485.	1.0	31
41	Rapidly changing landscape of PET/CT imaging in prostate cancer. Current Opinion in Urology, 2016, 26, 493-500.	0.9	7
42	Epididymal Metastasis of Prostate Cancer Detected With 68Ga-PSMA-PET/CT. Clinical Nuclear Medicine, 2016, 41, 792-793.	0.7	7
43	Healing Sacral Fracture Masquerading as Metastatic Bone Disease on a 68Ga-PSMA PET/CT. Clinical Nuclear Medicine, 2016, 41, e346-e347.	0.7	48
44	PET-CT in the UK: current status and future directions. Clinical Radiology, 2016, 71, 673-690.	0.5	22
45	11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1971-1979.	3.3	79
46	Nuclear Medicine Imaging of Prostate Cancer. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2016, 188, 1037-1044.	0.7	9
47	Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. Prostate, 2016, 76, 125-139.	1.2	17
48	Sensitivity, Specificity, and Predictors of Positive 68 Gaâ€“Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2016, 70, 926-937.	0.9	819
49	PET imaging in prostate cancer, future trends: PSMA ligands. Clinical and Translational Imaging, 2016, 4, 467-472.	1.1	6
50	68Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1288-1299.	3.3	58
51	Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 557-562.	2.8	155
52	Prostate Cancer Imaging with Novel PET Tracers. Current Urology Reports, 2016, 17, 18.	1.0	48
53	The Utility of Molecular Imaging in Prostate Cancer. Current Urology Reports, 2016, 17, 26.	1.0	15
54	New Clinical Indications for 18 F/ 11 C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. European Urology, 2016, 70, 161-175.	0.9	184
55	Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1546-1562.	3.3	37

#	Article	IF	Citations
56	Personalized precision radiotherapy by integration of multi-parametric functional and biological imaging in prostate cancer: A feasibility study. Zeitschrift Fur Medizinische Physik, 2017, 27, 21-30.	0.6	29
57	Prospective evaluation of 68Galliumâ€prostateâ€specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU International, 2017, 119, 209-215.	1.3	263
58	Toxicity and efficacy of salvage carbon 11â€choline positron emission tomography/computed tomographyâ€guided radiation therapy in patients with lymph node recurrence of prostate cancer. BJU International, 2017, 119, 406-413.	1.3	43
59	Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer. JAMA Oncology, 2017, 3, 1415.	3.4	42
60	Editorial Comment. Journal of Urology, 2017, 197, 682-683.	0.2	0
61	Toma de imÃ¡genes molecular del cÃ¡ncer de prÃ³stata: anÃ¡lisis de rendimiento de 68Ga-PSMA PET/TC frente a PET/TC colina. Actas UrolÃ³gicas EspaÃ±olas, 2017, 41, 292-299.	0.3	11
62	The Clinical Impact of Additional Late PET/CT Imaging with ⁶⁸Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 750-755.	2.8	105
63	Reply to Filippo Alongi, Rosario Mazzola, Dario Aiello and Matteo Salgarello's Letter to the Editor re: Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71:37â€“43. A Step Forward in the Era of Functional Imaging?. European Urology, 2017, 71, e123-e124.	0.9	0
64	Role of Imaging in the Era of Precision Medicine. Academic Radiology, 2017, 24, 639-649.	1.3	52
65	68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 941-949.	3.3	247
66	The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 788-800.	3.3	81
67	New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography. International Urology and Nephrology, 2017, 49, 803-810.	0.6	3
68	Detection Efficacy of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. Journal of Nuclear Medicine, 2017, 58, 1081-1087.	2.8	66
69	68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1014-1024.	3.3	589
70	Optimization of 18 F-Choline PET/CT acquisition in prostate cancer: Preliminary results concerning the length of the acquisition. Medecine Nucleaire, 2017, 41, 15-20.	0.2	0
71	PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1751-1776.	3.3	45
72	⁶⁸Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. Journal of Nuclear Medicine, 2017, 58, 1617-1623.	2.8	111
73	Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1258-1268.	3.3	425

#	Article	IF	Citations
74	Molecular imaging for prostate cancer: Performance analysis of 68 Ga-PSMA PET/CT versus choline PET/CT. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2017, 41, 292-299.	0.2	4
77	Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?. Journal of Nuclear Medicine, 2017, 58, 1186-1187.	2.8	4
78	Long-term Results of a Comparative PET/CT and PET/MRI Study of 11C-Acetate and 18F-Fluorocholine for Restaging of Early Recurrent Prostate Cancer. Clinical Nuclear Medicine, 2017, 42, e242-e246.	0.7	15
79	Diagnostic Accuracy of 64 Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience. Urology, 2017, 106, 139-145.	0.5	42
81	Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 670-677.	3.3	58
82	Value of ¹¹¹Inâ€prostateâ€specific membrane antigen (<scp>PSMA</scp>)â€radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical followâ€up. BJU International, 2017, 120, 40-47.	1.3	88
83	The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Nuclear Medicine Communications, 2017, 38, 149-155.	0.5	32
84	Impact of ⁶⁸Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1956-1961.	2.8	111
85	Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1636-1646.	3.3	17
86	Uptake in sympathetic ganglia on ⁶⁸Gaâ€<scp>PSMA</scp>â€<scp>HBED PET</scp>/<scp>CT</scp>: A potential pitfall in scan interpretation. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 732-738.	0.9	21
87	Frusemide aids diagnostic interpretation of ⁶⁸Gaâ€<scp>PSMA</scp> positron emission tomography/<scp>CT</scp> in men with prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 739-744.	0.9	23
88	Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1647-1655.	3.3	41
89	Clinical Applications of Radiolabeled Peptides for PET. Seminars in Nuclear Medicine, 2017, 47, 493-523.	2.5	49
90	Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1622-1635.	3.3	91
91	Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. Expert Review of Anticancer Therapy, 2017, 17, 625-633.	1.1	24
92	Initial multicentre experience of ⁶⁸galliumâ€PSMA PET/CT guided robotâ€assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJU International, 2017, 120, 673-681.	1.3	67
93	Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. Radiotherapy and Oncology, 2017, 122, 99-102.	0.3	38
95	Clinical impact of ⁶⁸Gaâ€prostateâ€specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostateâ€specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU International, 2017, 120, 197-203.	1.3	99

#	Article	IF	Citations
96	Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 776-787.	3.3	124
97	Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 765-775.	3.3	69
98	Managing Cancer Relapse After Radical Prostatectomy. Urologic Clinics of North America, 2017, 44, 597-609.	0.8	1
99	Molecular radiotheragnostics in prostate cancer. Clinical Medicine, 2017, 17, 458-461.	0.8	4
101	An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT. Clinical Nuclear Medicine, 2017, 42, e441-e443.	0.7	1
102	Performance of 68Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence. Current Urology Reports, 2017, 18, 84.	1.0	25
103	Seduction by Sensitivity: Reality, Illusion, or Delusion? The Challenge of Assessing Outcomes after PSMA Imaging Selection of Patients for Treatment. Journal of Nuclear Medicine, 2017, 58, 1969-1971.	2.8	22
104	Oligometastatic prostate cancer. Current Opinion in Urology, 2017, 27, 533-541.	0.9	30
105	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 67S-76S.	2.8	163
106	New aspects of molecular imaging in prostate cancer. Methods, 2017, 130, 36-41.	1.9	21
107	PET/CT in Prostate Cancer. , 2017, , .		0
109	Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography for staging of high-risk prostate cancer. Scandinavian Journal of Urology, 2017, 51, 498-501.	0.6	2
110	Treatment Outcomes from ⁶⁸Ga-PSMA PET/CTâ€“Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. Journal of Nuclear Medicine, 2017, 58, 1972-1976.	2.8	149
111	Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2117-2136.	3.3	234
113	Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy. European Urology Focus, 2017, 3, 538-544.	1.6	39
114	Longitudinal multi-parametric imaging in radiation oncology: boon or bane?. Acta OncolÃ³gica, 2017, 56, 501-502.	0.8	1
115	Improving the Imaging Contrast of ⁶⁸Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. Bioconjugate Chemistry, 2017, 28, 2485-2492.	1.8	40
116	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2017, , 883-923.		0

#	Article	IF	Citations
117	Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1-3.	3.3	3
118	PSMA Ligands for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1545-1552.	2.8	165
120	68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer. Nuclear Medicine and Molecular Imaging, 2017, 51, 314-322.	0.6	44
121	PSMA ligands in prostate cancer â€“ Probe optimization and theranostic applications. Methods, 2017, 130, 42-50.	1.9	43
122	Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer. Clinical and Translational Oncology, 2017, 19, 553-561.	1.2	12
123	The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. Prostate Cancer and Prostatic Diseases, 2017, 20, 85-92.	2.0	48
124	Toward the future of the functional imaging of advanced prostate cancer. European Urology Focus, 2017, 3, 240-242.	1.6	4
125	Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2017, 97, 526-535.	0.4	35
126	Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 92-101.	3.3	237
127	‹sup›68‹/sup›Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. Journal of Nuclear Medicine, 2017, 58, 81-84.	2.8	166
128	Rationale for Modernising Imaging in Advanced Prostate Cancer. European Urology Focus, 2017, 3, 223-239.	1.6	62
129	F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 678-688.	3.3	421
130	MR- und PET-Bildgebung der Prostata. , 2017, , .		3
131	Molecular Imaging and Precision Medicine in Prostate Cancer. PET Clinics, 2017, 12, 83-92.	1.5	9
132	Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. Technology in Cancer Research and Treatment, 2017, 16, 1194-1201.	0.8	37
133	Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 344-357.	1.8	3
134	Metal-Based PSMA Radioligands. Molecules, 2017, 22, 523.	1.7	45
135	Focal therapy for prostate cancer: the technical challenges. Journal of Contemporary Brachytherapy, 2017, 4, 383-389.	0.4	10

#	Article	IF	Citations
136	Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer. Journal of Contemporary Brachytherapy, 2017, 2, 161-166.	0.4	10
137	Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 168-180.	0.4	19
138	Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Research, 2017, 7, 77.	1.1	33
139	Advances in prostate-specific membrane antigen PET of prostate cancer. Current Opinion in Oncology, 2018, 30, 189-196.	1.1	24
140	Biochemical Recurrence of Prostate Cancer: Initial Results with [¹⁸F]PSMA-1007 PET/CT. Journal of Nuclear Medicine, 2018, 59, 632-635.	2.8	55
141	Recurrent Medullary Thyroid Carcinoma on 68Gaâ€“Prostate-Specific Membrane Antigen PET/CT. Clinical Nuclear Medicine, 2018, 43, 359-360.	0.7	22
142	Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes. Surgical Oncology, 2018, 27, 138-145.	0.8	27
143	Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA). Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1407-1416.	1.7	61
144	Theragnostic Target, Prostate-Specific Membrane Antigenâ€”Also Specific for Nonprostatic Malignancies. International Journal of Radiation Oncology Biology Physics, 2018, 101, 646-649.	0.4	6
145	Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands. World Journal of Urology, 2018, 36, 603-608.	1.2	28
146	Targeting PSMA by radioligands in non-prostate diseaseâ€”current status and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 860-877.	3.3	114
147	Current status of theranostics in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 471-495.	3.3	115
148	68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence. Nuclear Medicine Communications, 2018, 39, 179-185.	0.5	13
149	Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics, 2018, 38, 200-217.	1.4	262
150	Contribution of 11 C-Choline PET/CT in prostate carcinoma biochemical relapse with serum PSA level below 1 ng/ml. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 156-162.	0.1	5
151	68 Ga-PSMA PET/CT in prostate cancer. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 130-138.	0.1	4
152	Simplified and robust oneâ€step radiosynthesis of [¹⁸F]DCFPyL via direct radiofluorination and cartridgeâ€based purification. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 757-763.	0.5	11
153	Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue. Scientific Reports, 2018, 8, 4997.	1.6	39

#	Article	IF	Citations
154	Prostate-Specific Membrane Antigen Expression in Adrenocortical Carcinoma on 68Gaâ€“Prostate-Specific Membrane Antigen PET/CT. Clinical Nuclear Medicine, 2018, 43, 449-451.	0.7	9
155	68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2018, 4, 686-693.	1.6	195
156	Ultraâ€‹small superparamagnetic iron oxides for metastatic lymph node detection: back on the block. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2018, 10, e1471.	3.3	70
157	The Impact of ⁶⁸Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. Journal of Nuclear Medicine, 2018, 59, 82-88.	2.8	281
159	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	0.9	488
160	Impact of ⁶⁸Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management. Journal of Nuclear Medicine, 2018, 59, 89-92.	2.8	58
161	⁶⁸Gaâ€‹<scp>PSMA PET</scp>/<scp>CT</scp> for the detection of bone metastases in prostate cancer: a systematic review of the published literature. Clinical Physiology and Functional Imaging, 2018, 38, 911-922.	0.5	56
162	La PET/TC con 68 Ga-PSMA en el cÃ¡ncer de prÃ³stata. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 130-138.	0.0	13
163	Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer. Current Opinion in Urology, 2018, 28, 191-196.	0.9	16
164	Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigenâ€“Targeted PET Imaging: PSMA-RADS Version 1.0. Journal of Nuclear Medicine, 2018, 59, 479-485.	2.8	122
165	⁶⁴CuCl₂ PET/CT in Prostate Cancer Relapse. Journal of Nuclear Medicine, 2018, 59, 444-451.	2.8	57
166	Oligometastases in prostate cancer. Strahlentherapie Und Onkologie, 2018, 194, 318-324.	1.0	30
167	The use of PET/CT in prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 4-21.	2.0	70
168	Impact of ⁶⁸Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. Journal of Nuclear Medicine, 2018, 59, 434-441.	2.8	113
169	^{99m}Tcâ€MIPâ€1404â€SPECT/CT for the detection of PSMAâ€positive lesions in 225 patients with biochemical recurrence of prostate cancer. Prostate, 2018, 78, 54-63.	1.2	61
170	AportaciÃ³n de la PET/TC con 11 C-colina en la recidiva bioquÃmica del cÃ¡ncer de prÃ³stata con antÃgeno especÃfico prostÃ¡tico sÃ©rico inferior a 1 ng/ml. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 156-162.	0.0	5
171	⁶⁸Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. Journal of Nuclear Medicine, 2018, 59, 230-237.	2.8	226
172	Delineating sites of failure following post-prostatectomy radiation treatment using 68 Ga-PSMA-PET. Radiotherapy and Oncology, 2018, 126, 244-248.	0.3	27

#	Article	IF	Citations
173	Prostate cancerâ€“specific PET radiotracers: A review on the clinical utility in recurrent disease. Practical Radiation Oncology, 2018, 8, 28-39.	1.1	140
174	Gallium 68-PSMA PET/CT for lesion characterization in suspected cases of prostate carcinoma. Nuclear Medicine Communications, 2018, 39, 1013-1021.	0.5	10
177	Optimization of temporal sampling for 18F-choline uptake quantification in prostate cancer assessment. EJNMMI Research, 2018, 8, 49.	1.1	3
178	68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, 579-585.	0.7	24
179	Clinical implications of PET/CT in prostate cancer management. Translational Andrology and Urology, 2018, 7, 844-854.	0.6	20
180	Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 892-899.	0.7	19
181	The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 462-478.	3.9	65
182	Worth a local treatment? â€“ Analysis of modern radiotherapy concepts for oligometastatic prostate cancer. Radiation Oncology, 2018, 13, 185.	1.2	4
183	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncology, The, 2018, 19, e534-e545.	5.1	98
184	The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2253-2255.	3.3	0
186	Comparative study between ⁶⁸Gaâ€prostateâ€specific membrane antigen positron emission tomography and conventional imaging in the initial staging of prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 816-822.	0.9	23
187	Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges. Korean Journal of Radiology, 2018, 19, 819.	1.5	29
188	Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: A systematic review. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 692-706.	0.9	24
189	Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. British Journal of Radiology, 2018, 91, 20180308.	1.0	50
190	Application of Cu-64 NODAGA-PSMA PET in Prostate Cancer. Advances in Therapy, 2018, 35, 779-784.	1.3	16
192	Place of modern imaging in brachytherapy planning. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 326-333.	0.6	12
193	Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1873-1883.	3.3	41
195	Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. European Urology Oncology, 2018, 1, 531-537.	2.6	106

#	Article	IF	Citations
196	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. American Journal of Roentgenology, 2018, 211, 286-294.	1.0	25
197	68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2035-2044.	3.3	72
198	Prostate cancer imaging: when the game gets tough, the hard one gets done!. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2032-2034.	3.3	0
199	PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications. Current Radiopharmaceuticals, 2018, 11, 4-13.	0.3	28
200	Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer. Diagnostics, 2018, 8, 16.	1.3	90
201	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2045-2054.	3.3	116
203	One-year experience with 68Ga-PSMA PET/CT: applications and results in biochemical recurrence of prostate cancer. Radiologia Brasileira, 2018, 51, 151-155.	0.3	6
204	Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Radiation Oncology, 2018, 13, 37.	1.2	54
205	68Ga-PSMA and 11C-Choline comparison using a tri-modality PET/CT-MRI (3.0ÂT) system with a dedicated shuttle. European Journal of Hybrid Imaging, 2018, 2, 9.	0.6	17
206	A prospective randomized multicentre study of the impact of galliumâ€68 prostateâ€specific membrane antigen (PSMA) PET/CT imaging for staging highâ€risk prostate cancer prior to curativeâ€intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU International, 2018, 122, 783-793.	1.3	96
207	68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer. Radiologia Medica, 2018, 123, 952-965.	4.7	16
208	Positronâ€emission tomography imaging in urological oncology: Current aspects and developments. International Journal of Urology, 2018, 25, 912-921.	0.5	10
209	PSMA Theranostics: Current Status and Future Directions. Molecular Imaging, 2018, 17, 153601211877606.	0.7	150
210	Advances in Urologic Imaging. Urologic Clinics of North America, 2018, 45, 503-524.	0.8	27
211	68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5Âng/ml. Efficacy and impact on treatment strategy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 11-19.	3.3	96
212	Detection Efficacy of ¹⁸F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. Journal of Nuclear Medicine, 2019, 60, 362-368.	2.8	238
213	68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. European Radiology, 2019, 29, 1221-1230.	2.3	63
214	Managing Nonmetastatic Castration-resistant Prostate Cancer. European Urology, 2019, 75, 285-293.	0.9	125

#	Article	IF	Citations
215	Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies. Prostate Cancer and Prostatic Diseases, 2019, 22, 16-23.	2.0	22
216	Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row. World Journal of Urology, 2019, 37, 2607-2613.	1.2	18
218	Prostateâ€Specific Membrane Antigen (PSMA)â€Targeted Radionuclide Probes for Imaging and Therapy of Prostate Cancer. Asian Journal of Organic Chemistry, 2019, 8, 1588-1600.	1.3	7
219	Salvage lymph node dissection in hormone-naÃ¯ve men: How effective is surgery?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 812.e17-812.e24.	0.8	6
220	18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncology, The, 2019, 20, 1286-1294.	5.1	338
221	Enhancing PSMA-uptake with androgen deprivation therapy â€“ a new way to detect prostate cancer metastases?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 459-467.	0.7	18
222	ï»¿68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients. Nuklearmedizin - NuclearMedicine, 2019, 58, 352-362.	0.3	9
223	Prostate-Specific Membrane Antigen PET/Magnetic Resonance Imaging for the Planning of Salvage Radiotherapy in Patients with Prostate Cancer with Biochemical Recurrence After Radical Prostatectomy. PET Clinics, 2019, 14, 487-498.	1.5	2
224	Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer. Frontiers in Oncology, 2019, 9, 781.	1.3	7
225	Male Breast Cancer Detected by 68Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis. Clinical Genitourinary Cancer, 2019, 17, 154-156.	0.9	9
226	Detection Rate of ¹⁸F-Choline PET/CT and ⁶⁸Ga-PSMA-HBED-CC PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes. Journal of Nuclear Medicine, 2019, 60, 971-977.	2.8	35
227	Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications. Annual Review of Medicine, 2019, 70, 461-477.	5.0	50
228	24 Urological Tumors. , 2019, , .		0
229	Detection rates of recurrent prostate cancer: ⁶⁸Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET/CT scans. A systematic review. Therapeutic Advances in Urology, 2019, 11, 175628721881579.	0.9	18
231	Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skeletal Radiology, 2019, 48, 1915-1924.	1.2	92
232	Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 2019, 140, 68-75.	0.3	20
233	Risk-adapted moderate hypofractionation of prostate cancer. Strahlentherapie Und Onkologie, 2019, 195, 894-901.	1.0	5
234	⁶⁸Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. Cancer Biology and Medicine, 2019, 16, 157.	1.4	12

#	Article	IF	Citations
235	How does ⁶⁸Gaâ€prostateâ€specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?. International Journal of Urology, 2019, 26, 804-811.	0.5	21
236	The Evolving Role of Prostate-Specific Membrane Antigenâ€"Based Diagnostics and Therapeutics in Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 321-330.	1.8	33
238	Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer?. European Urology, 2019, 76, 265-267.	0.9	9
239	Novel Imaging in Detection of Metastatic Prostate Cancer. Current Oncology Reports, 2019, 21, 31.	1.8	13
240	Molecular Imaging of Recurrent and Metastatic Prostate Cancer. Seminars in Nuclear Medicine, 2019, 49, 280-293.	2.5	12
241	Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. JAMA Oncology, 2019, 5, 856.	3.4	493
242	New Targets for PET Molecular Imaging of Prostate Cancer. Seminars in Nuclear Medicine, 2019, 49, 326-336.	2.5	21
244	Metastatic castrationâ€sensitive prostate cancer: Abiraterone, docetaxel, orâ€¦. Cancer, 2019, 125, 1777-1788.	2.0	50
247	A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. European Urology Oncology, 2019, 2, 47-76.	2.6	140
248	Impact of access to novel therapies on the initial management of castrateâ€resistant prostate cancer: an Australian multicentre study. Internal Medicine Journal, 2019, 49, 1378-1385.	0.5	4
249	Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. European Urology Oncology, 2019, 2, 152-162.	2.6	29
250	Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer. Clinical Nuclear Medicine, 2019, 44, e629-e633.	0.7	20
251	Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories. Journal of Nuclear Medicine, 2019, 60, 511-516.	2.8	29
252	Correlation between PSA kinetics and PSMAâ€PET in prostate cancer restaging: A metaâ€analysis. European Journal of Clinical Investigation, 2019, 49, e13063.	1.7	42
253	⁶⁸Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery. British Journal of Radiology, 2019, 92, 20180667.	1.0	16
254	Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer. Urology, 2019, 125, 154-162.	0.5	20
255	Assessment of 68Ga-PSMA-11 PET positivity predictive factors in prostate cancer. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2019, 38, 22-28.	0.1	1
256	Ductal Carcinoma of the Prostate: An Uncommon Entity With Atypical Behaviour. Clinical Oncology, 2019, 31, 108-114.	0.6	18

#	Article	IF	Citations
257	Prospective, Multisite, International Comparison of ¹⁸F-Fluoromethylcholine PET/CT, Multiparametric MRI, and ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. Journal of Nuclear Medicine, 2019, 60, 794-800.	2.8	61
258	Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 910-916.	2.8	35
259	11C-choline PET/CT predicts survival in prostate cancer patients with PSAâ€‰<â€‰1 NG/ml. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 921-929.	3.3	14
260	A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). International Journal of Radiation Oncology Biology Physics, 2019, 103, 335-343.	0.4	56
261	ValoraciÃ³n de factores predictivos de positividad en PET con 68Ga-PSMA-11 en el cÃ¡ncer de prÃ³stata. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2019, 38, 22-28.	0.0	2
262	Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer, 2019, 19, 18.	1.1	86
263	Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone. Journal of Nuclear Medicine, 2019, 60, 1111-1117.	2.8	23
264	68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 31-39.	3.3	74
265	Impact of sodium 18F-fluoride PET/CT, 18F-fluorocholine PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study. World Journal of Urology, 2019, 37, 1587-1595.	1.2	10
266	Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. Clinical Genitourinary Cancer, 2019, 17, e53-e55.	0.9	8
267	Metaanalysis of ⁶⁸Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. Journal of Nuclear Medicine, 2019, 60, 786-793.	2.8	169
268	Voxelâ€wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework. BJU International, 2019, 123, 1020-1030.	1.3	9
269	Impact of ⁶⁸Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. Journal of Nuclear Medicine, 2019, 60, 963-970.	2.8	44
270	68Gaâ€PSMAâ€11 PETâ€CT study in prostate cancer patients with biochemical recurrence and nonâ€contributive 18Fâ€Choline PETâ€CT: Impact on therapeutic decisionâ€making and biomarker changes. Prostate, 2019, 79, 454-461.	1.2	14
271	Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 889-900.	3.3	44
272	Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. Journal of Nuclear Medicine, 2019, 60, 517-523.	2.8	285
273	Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis. Urologia Internationalis, 2019, 102, 27-36.	0.6	45
274	Imaging for the Detection of Locoregional Recurrences in Biochemical Progression After Radical Prostatectomyâ€”A Systematic Review. European Urology Focus, 2019, 5, 550-560.	1.6	32

#	Article	IF	Citations
275	Prospective Evaluation of PSMA-Targeted ¹⁸F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 58-61.	2.8	61
276	Head-to-Head Comparison of ⁶⁸Ga-PSMA-11 with ¹⁸F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. Journal of Nuclear Medicine, 2020, 61, 527-532.	2.8	142
277	Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: aÂmulti-institutional analysis. Strahlentherapie Und Onkologie, 2020, 196, 213-221.	1.0	29
278	Detection Rate and Localization of Prostate Cancer Recurrence Using ⁶⁸Ga-PSMA-11 PET/MRI in Patients with Low PSA Values â‰¤ 0.5 ng/mL. Journal of Nuclear Medicine, 2020, 61, 194-201.	2.8	39
279	Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 136-146.	3.3	56
280	Prostate-Specific Membrane Antigenâ€“Guided Surgery. Journal of Nuclear Medicine, 2020, 61, 6-12.	2.8	31
281	3-Year Freedom from Progression After ⁶⁸Ga-PSMA PET/CTâ€“Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. Journal of Nuclear Medicine, 2020, 61, 866-872.	2.8	86
282	68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancerâ€”a modified protocol compared with the common protocol. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 624-631.	3.3	26
283	Use of galliumâ€68 prostateâ€specific membrane antigen positronâ€emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. BJU International, 2020, 125, 206-214.	1.3	80
284	¹¹C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series. Journal of Nuclear Medicine, 2020, 61, 827-833.	2.8	18
286	Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?. Bioconjugate Chemistry, 2020, 31, 375-395.	1.8	38
287	Deep learningâ€based quantification of PET/CT prostate gland uptake: association with overall survival. Clinical Physiology and Functional Imaging, 2020, 40, 106-113.	0.5	32
288	Promise of PET imaging in prostate cancer. Current Opinion in Urology, 2020, 30, 9-16.	0.9	2
289	Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 652-664.	3.3	38
290	The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castrationâ€“resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 695-712.	3.3	37
291	10-Year Clinical Experience With 18F-Choline PET/CT. Clinical Nuclear Medicine, 2020, 45, 594-603.	0.7	6
292	Molecular imaging of prostate cancer: Review of imaging agents, modalities, and current status. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2020, 44, 386-399.	0.2	0
293	68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer. PLoS ONE, 2020, 15, e0240892.	1.1	18

#	Article	IF	Citations
294	FDG-PET Versus PSMA-PET: A Patient With Prostate Cancer. Journal of Investigative Medicine High Impact Case Reports, 2020, 8, 232470962094131.	0.3	6
295	Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer. Seminars in Oncology Nursing, 2020, 36, 151052.	0.7	3
296	Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis. Cancers, 2020, 12, 3395.	1.7	7
297	The Impact of 18F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 1364-1369.	0.6	5
298	Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?. Cancer Imaging, 2020, 20, 58.	1.2	10
299	Histologic validation of auto-contoured dominant intraprostatic lesions on [18F] DCFPyL PSMA-PET imaging. Radiotherapy and Oncology, 2020, 152, 34-41.	0.3	8
300	Patterns of Lymph Node Failure in Patients With Recurrent Prostate Cancer Postradical Prostatectomy and Implications for Salvage Therapies. Advances in Radiation Oncology, 2020, 5, 1126-1140.	0.6	9
301	Predictive value of Prostate Specific Antigen variations in the last week of salvage radiotherapy for biochemical recurrence of prostate cancer after surgery: A practical approach. Cancer Reports, 2020, 3, e1285.	0.6	4
303	Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence. Current Opinion in Urology, 2020, Publish Ahead of Print, 635-640.	0.9	3
304	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296.	1.2	16
306	Inguinal Canal Depositâ€"An Uncommon Site of Metastases in Carcinoma Prostate Detected on 68Gaâ€"Prostate-Specific Membrane Antigen PET/CT. Clinical Nuclear Medicine, 2020, 45, e443-e444.	0.7	2
307	Clinical impact of PET imaging in prostate cancer management. Current Opinion in Urology, 2020, Publish Ahead of Print, 649-653.	0.9	1
308	Detection of Recurrent Prostate Cancer With 18F-Fluciclovine PET/MRI. Frontiers in Oncology, 2020, 10, 582092.	1.3	9
309	Prognostic and Predictive Biomarkers in Oligometastatic Disease. Cancer Journal (Sudbury, Mass), 2020, 26, 100-107.	1.0	8
310	[¹⁸F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open, 2020, 10, e035959.	0.8	8
311	Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer. Clinical and Translational Oncology, 2020, 22, 2236-2243.	1.2	4
312	Impact of ⁶⁸Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. Journal of Nuclear Medicine, 2020, 61, 1793-1799.	2.8	74
313	PSMA-Ligand Imaging in the Diagnosis of Prostate Cancer. , 2020, , 755-763.		1

#	Article	IF	Citations
314	TEP/TDM 18F-choline dans les rÃ©cidives biologiques des cancers de la prostate traites par radiothÃ©rapie externe ou curiethÃ©rapieÂ: impact du PSA et de sa cinÃ©tique. Medecine Nucleaire, 2020, 44, 53-64.	0.2	0
315	PSMA-targeted Radiotracers versus ¹⁸F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. Radiology, 2020, 296, 44-55.	3.6	49
316	The Role of PET-CT Imaging in Prostate Cancer. Seminars in Ultrasound, CT and MRI, 2020, 41, 373-391.	0.7	1
317	PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. Cancers, 2020, 12, 1367.	1.7	75
318	Non-metastatic castration-resistant prostate cancer: current status and future directions. Expert Review of Anticancer Therapy, 2020, 20, 513-522.	1.1	4
319	Prostate MRI Essentials. , 2020, , .		1
320	68Ga-labeled PSMA-11Â(68Ga-isoPROtrace-11) synthesized with ready to use kit: normal biodistribution and uptake characteristics of tumour lesions. Scientific Reports, 2020, 10, 3109.	1.6	17
321	Radiotherapy in the Management of Metastatic Hormone-Sensitive Prostate Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 87-93.	1.0	4
322	Protocol for the PRIMARY clinical trial, a prospective, multicentre, crossâ€sectional study of the additive diagnostic value of galliumâ€68 prostateâ€specific membrane antigen positronâ€emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU International, 2020, 125, 515-524.	1.3	51
323	PSMA-positive nodal recurrence in prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 637-646.	1.0	7
324	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. Journal of Nuclear Medicine, 2020, 61, 552-562.	2.8	10
325	Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT: impact of postoperative treatments. World Journal of Urology, 2021, 39, 399-406.	1.2	4
326	Novel PET imaging methods for prostate cancer. World Journal of Urology, 2021, 39, 687-699.	1.2	12
327	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part IIâ€"2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology, 2021, 79, 263-282.	0.9	633
328	Thyroid and androgen receptor signaling are antagonized by Î¼â€Crystallin in prostate cancer. International Journal of Cancer, 2021, 148, 731-747.	2.3	17
329	Role of ¹⁸F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review. American Journal of Roentgenology, 2021, 216, 851-859.	1.0	13
330	Salvage Therapy for Prostate Cancer. , 2021, , .		0
331	Current and emerging therapies for localized high-risk prostate cancer. Expert Review of Anticancer Therapy, 2021, 21, 267-282.	1.1	3

#	Article	IF	Citations
332	18F-Choline, 68Ga-PSMA-11 and 18F-FDG PET/CT in Treatment Response Evaluation: Prostate Cancer. , 2021, , 261-295.		0
333	Change of management by using hybrid imaging with radiolabelled choline in biochemical recurrent prostate cancer: a systematic review and a meta-analysis. Clinical and Translational Imaging, 2021, 9, 57-71.	1.1	0
334	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1626-1638.	3.3	188
335	Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA. Scientific Reports, 2021, 11, 4726.	1.6	18
336	Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2978-2989.	3.3	58
337	Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2960-2969.	3.3	8
338	Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, 596-604.	2.8	79
339	Mesorectal Lymph Node Metastases as Index Lesion in 68Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer. Frontiers in Surgery, 2021, 8, 637134.	0.6	0
340	Patterns of primary staging for newly diagnosed prostate cancer in the era of prostate specific membrane antigen positron emission tomography: A populationâ€based analysis. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 649-654.	0.9	4
341	68Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy. Diagnostics, 2021, 11, 622.	1.3	6
342	Detection Efficacy of ¹⁸Fâ€hPSMAâ€7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment. Journal of Nuclear Medicine, 2021, 62, 1719-1726.	2.8	14
343	Prostate specific membrane antigen positron emission tomography/computed tomography and staging high risk prostate cancer: a non-systematic review of high clinical impact literature. Minerva Urology and Nephrology, 2021, 73, 32-41.	1.3	5
345	Adaptive sequential plan-on-plan optimization during prostate-specific antigen response guided radiotherapy of recurrent prostate cancer. Physics and Imaging in Radiation Oncology, 2021, 18, 5-10.	1.2	1
346	Critical Role of 2-[18F]-fluoro-2-deoxy-glucose in Hormonally Active Malignancies. PET Clinics, 2021, 16, 177-189.	1.5	1
347	Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer. EJNMMI Research, 2021, 11, 41.	1.1	12
348	Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3702-3711.	3.3	15
349	Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies. European Urology Open Science, 2021, 27, 19-28.	0.2	11
351	Response to the letter to the Editor by Professors Francesco Giammarile and Stefano Fanti regarding our article â€œSurvey by the ANSM of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CTâ€• European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2692-2695.	3.3	0

#	Article	IF	Citations
352	Vesicoâ€urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy. BJU International, 2021, 127, 23-29.	1.3	1
353	Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. BMC Cancer, 2021, 21, 512.	1.1	14
355	PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer. Medical Oncology, 2021, 38, 89.	1.2	16
357	The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis. Frontiers in Oncology, 2021, 11, 684629.	1.3	37
358	Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 484-494.	0.7	4
359	Diagnostic Performance and Clinical Impact of ⁶⁸Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study). Journal of Nuclear Medicine, 2022, 63, 240-247.	2.8	28
360	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.3	2
362	Value of PET imaging for radiation therapy. Strahlentherapie Und Onkologie, 2021, 197, 1-23.	1.0	16
363	Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience. Nuclear Medicine Communications, 2021, 42, 1254-1260.	0.5	7
364	Salvage therapy for prostate cancer after radical prostatectomy. Nature Reviews Urology, 2021, 18, 643-668.	1.9	26
365	Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer. European Radiology, 2022, 32, 901-911.	2.3	11
366	What to Trust, PSA or [68Ga]Ga-PSMA-11: Learn from Experience. Research and Reports in Urology, 2021, Volume 13, 597-601.	0.6	0
367	PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer. Clinical and Translational Radiation Oncology, 2021, 30, 1-6.	0.9	12
368	Artificial intelligence-based measurements of PET/CT imaging biomarkers are associated with disease-specific survival of high-risk prostate cancer patients. Scandinavian Journal of Urology, 2021, 55, 427-433.	0.6	2
369	PSMAâ€positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state. Prostate, 2021, 81, 1390-1401.	1.2	14
370	Head-to-head comparison of [68ÂGa]Ga-P16-093 and [68ÂGa]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1052-1062.	3.3	10
371	Implementation of radioguided surgery in prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 202-214.	0.4	1
372	Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. JAMA Oncology, 2021, 7, 1635.	3.4	138

#	Article	IF	Citations
373	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. European Urology, 2021, 80, 374-382.	0.9	49
374	Prostate cancer: Molecular imaging and MRI. European Journal of Radiology, 2021, 143, 109893.	1.2	6
375	Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2935-2950.	3.3	14
376	68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?. Wiener Medizinische Wochenschrift, 2019, 169, 3-11.	0.5	14
379	Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. Journal of Urology, 2020, 204, 496-502.	0.2	12
380	Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. PLoS ONE, 2020, 15, e0239414.	1.1	6
381	68Ga-Prostate-specific membrane antigen (PSMA) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 705-729.	0.7	11
382	68Ga-PSMA-PET/CT Î—as a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease. Anticancer Research, 2017, 37, 2753-2760.	0.5	10
383	Predictor of 68Ga PSMA PET/CT positivity in patients with prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 226-230.	0.4	2
384	Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 7-18.	0.4	19
385	Copper, PET/CT and prostate cancer: a systematic review of the literature. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 382-392.	0.4	6
386	Rare sites of metastases in prostate cancer detected on ga-68 psma pet/ct scanâ€"a case series. Indian Journal of Nuclear Medicine, 2017, 32, 13.	0.1	18
387	Incremental value of Ga-68 prostate-specific membrane antigen-11 positron-emission tomography/computed tomography scan for preoperative risk stratification of prostate cancer. Indian Journal of Nuclear Medicine, 2020, 35, 93.	0.1	9
388	Role of Early Dynamic Positron Emission Tomography/Computed Tomography with 68Ga-prostate-specific Membrane Antigen-HBED-CC in Patients with Adenocarcinoma Prostate: Initial Results. Indian Journal of Nuclear Medicine, 2018, 33, 112.	0.1	5
389	Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients. World Journal of Nuclear Medicine, 2019, 18, 244-250.	0.3	11
390	Anatomical mapping of lymph nodes in patients receiving salvage lymphadenectomy based on a positive 11C-choline positron emission tomography/computed tomography scan. Central European Journal of Urology, 2019, 72, 232-239.	0.2	2
391	Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection. World Journal of Men?s Health, 2020, 38, 32.	1.7	2
392	Single-Center Comparison of [64Cu]-DOTAGA-PSMA and [18F]-PSMA PETâ€"CT for Imaging Prostate Cancer. Current Oncology, 2021, 28, 4167-4173.	0.9	2

#	Article	IF	Citations
394	Prognostic role of 11Câ€¢choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy. Prostate, 2022, 82, 41-48.	1.2	3
395	Oligometastatic Disease Detection with 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact. Cancers, 2021, 13, 4982.	1.7	12
396	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2016, , 1-41.		0
397	New Radiopharmaceutical Markers for Metabolism and Receptor. , 2017, , 95-104.		0
398	Nuclear Medicine (Bone Scan, Choline and PSMA PET/CT). , 2017, , 127-141.		0
399	Diagnosis, Clinical Workup, and TNM Classification. , 2017, , 143-159.		0
400	Determining Focal Therapy Failure and Salvage Options. Current Clinical Urology, 2017, , 443-446.	0.0	0
401	Role of Radiolabelled Small Molecules Binding to PSMA in Diagnosis and Therapy of Prostate Cancer. , 2017, , 51-58.		1
402	Physikalisch-technische Grundlagen und Tracerentwicklung in der Positronenemissionstomografie. , 2017, , 19-56.		0
403	Local and Systemic Staging by Modern Imaging Modalities in Prostate Cancer. , 2018, , 1-15.		0
406	Local and Systemic Staging by Modern Imaging Modalities in Prostate Cancer. , 2019, , 125-139.		0
407	18F-PSMA-1007 and 18F-fluorocholine PET/CT in prostate cancer progression diagnostics. First comparative experience. Onkourologiya, 2019, 15, 70-76.	0.1	0
410	TÃ©cnicas de imagen molecular en el cÃ¡ncer de prÃ³stata: revisiÃ³n de radiofÃ¡rmacos, modalidades y evidencia actual. Actas UrolÃ³gicas EspaÃ±olas, 2020, 44, 386-399.	0.3	0
411	Radiomics for Identification and Prediction in Metastatic Prostate Cancer: A Review of Studies. Frontiers in Oncology, 2021, 11, 771787.	1.3	23
412	Molecular Imaging of Prostate Cancer. , 2020, , 171-190.		0
414	Clinicopathological correlation of pre-biopsy quantitative PSMA uptake in patients with persistently raised serum PSA: initial experience in 74 patients with simultaneous 68-Ga PSMA PET/MRI. Journal of Clinical Urology, 2022, 15, 186-192.	0.1	1
416	Urologic Imaging. , 2020, , 201-256.		1
417	Novel imaging in prostate cancer. Urology Annals, 2020, 12, 205.	0.3	2

#	Article	IF	Citations
418	Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526). International Journal of Radiation Oncology Biology Physics, 2022, 112, 1115-1122.	0.4	21
419	Clinical Staging/Diagnostic Imaging in Salvage Therapy for Prostate Cancer. , 2021, , 75-78.		0
420	The Role of PET in Salvage Therapy for Prostate Cancer. , 2021, , 89-114.		0
421	Radiotherapy for patients with locoregional and oligometastatic relapses of prostate cancer after radical prostatectomy. Onkourologiya, 2020, 16, 102-108.	0.1	0
422	Performance characteristics and relationship of PSA value/kinetics on carbon-11 acetate PET/CT imaging in biochemical relapse of prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 1-11.	1.0	11
423	68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?. Central European Journal of Urology, 2017, 70, 37-43.	0.2	7
424	Imaging in Prostate Cancer: Magnetic Resonance Imaging and Beyond. Missouri Medicine, 2018, 115, 135-141.	0.3	2
425	Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 127-139.	1.0	26
426	[Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 349-374.	1.0	14
427	Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?. Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211051870.	1.4	1
428	Advances in urologic oncology â€œOncoUrology Forum Special Editionâ€• The best of 2020. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2021, , .	0.2	0
429	Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110518.	1.4	3
430	In Reply to Onal etÂal. Clinical Oncology, 2022, , .	0.6	0
431	Pelvic lymph node dissection in high-risk prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2022, 48, 54-66.	0.7	6
432	Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2436-2444.	3.3	19
433	Modern possibilities of application ^{99m}Tc-labeled prostate-specific membrane antigen ligands in prostate cancer. Onkourologiya, 2022, 17, 136-150.	0.1	1
434	Theragnostics in prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 65, 333-341.	0.4	3
435	Evaluation of hybrid PET/CT imaging with the 68Ga-labelled PSMA ligand in patients with prostate cancer and biochemical progression in the low-range values of PSA after radical prostatectomy. Scripta Scientifica Medica, 2022, 54, 29.	0.1	0

#	Article	IF	Citations
436	Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer. Cancers, 2022, 14, 1169.	1.7	15
437	Application of 68Ga-PSMA-11 PET/CT in the Diagnosis of Prostate Cancer Clinical Relapse. Current Radiopharmaceuticals, 2022, 15, .	0.3	1
439	Robot-assisted Prostate-specific Membrane Antigenâ€“radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study. European Urology, 2022, 82, 97-105.	0.9	37
440	Stereotactic radiotherapy for oligometastases in the lymph nodes. Reports of Practical Oncology and Radiotherapy, 2022, 27, 46-51.	0.3	2
441	The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 126-135.	0.1	1
442	New Radionuclides and Technological Advances in SPECT and PET Scanners. Cancers, 2021, 13, 6183.	1.7	16
443	Postoperative radiotherapy in prostate cancer: When and how?Ââ€“ÂAn update review. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, , .	0.6	1
444	Biology of Cancer and PET Imaging: Pictorial Review. Journal of Nuclear Medicine Technology, 2022, 50, 81-89.	0.4	3
445	Role of 68Ga and 18F PSMA PET/CT and PET/MRI in biochemical recurrence of prostate cancer: a systematic review of prospective studies. Nuclear Medicine Communications, 2022, 43, 631-637.	0.5	6
446	Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging. Molecular Imaging and Biology, 2022, , 1.	1.3	2
447	Diagnostic Performance of Preoperative Choline-PET/CT in Patients Undergoing Salvage Lymph Node Dissection for Recurrent Prostate Cancer: A Multicenter Experience. Tomography, 2022, 8, 1090-1096.	0.8	1
455	Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis. European Radiology, 2022, 32, 7374-7385.	2.3	11
456	The role of prostate-specific membrane antigen PET/computed tomography in the management of prostate cancer patients: could we ask for more?. Current Opinion in Urology, 2022, 32, 269-276.	0.9	2
457	Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends. Journal of Clinical Medicine, 2022, 11, 2738.	1.0	12
458	First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. European Urology Oncology, 2022, 5, 377-387.	2.6	4
459	The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence. Frontiers in Endocrinology, 2022, 13, .	1.5	1
460	Evaluation of the Relationship Between Prostate-Specific Antigen Levels, Gleason Scores, and 68Ga-PSMA PET/CT Scan Findings in Prostate Cancer Patients. Iranian Journal of Radiology, 2022, 19, .	0.1	0
461	Mapping of Local Recurrences After Radical Prostatectomy Using 68-Galliumâ€“Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: Implications for Postprostatectomy Radiation Therapy Clinical Target Volumes. International Journal of Radiation Oncology Biology Physics, 2023, 115, 106-117.	0.4	6

#	Article	IF	Citations
462	Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics. European Radiology Experimental, 2022, 6, .	1.7	28
463	18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial. European Urology, 2022, 82, 501-509.	0.9	16
464	The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer. Nature Reviews Urology, 2022, 19, 475-493.	1.9	12
465	18F-PSMA-11 as an Attractive 68Ga-PSMA-11 Alternative for Prostate Cancer Imaging. European Urology, 2022, , .	0.9	0
466	Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends. Clinical Drug Investigation, 2022, 42, 631-642.	1.1	9
467	PSMA as a Target for Advanced Prostate Cancer: A Systematic Review. Frontiers in Urology, 0, 2, .	0.2	2
468	The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancerâ€"A Practical Clinical Review. Cancers, 2022, 14, 3638.	1.7	13
469	Penile metastasis in prostate cancer patients: Two case reports, surgical excision technique, and literature review. Current Urology, 0, Publish Ahead of Print, .	0.4	1
470	Clinical Applications of PSMA PET Examination in Patients with Prostate Cancer. Cancers, 2022, 14, 3768.	1.7	9
471	Prostate Cancer Biochemical Recurrence Resulted Negative on [68Ga]Ga-PSMA-11 but Positive on [18F]Fluoromethylcholine PET/CT. Tomography, 2022, 8, 2471-2474.	0.8	6
472	The Added Value of [18F]Choline PET/CT in Low-Risk Prostate Cancer Staging: A Case Report. Life, 2022, 12, 1728.	1.1	1
473	Comparison of 18F-PSMA-1007 PET/CT With 68Ga-PSMA-11 PET/CT for Initial Staging in Intermediate- and High-Risk Prostate Cancer. Clinical Nuclear Medicine, 2023, 48, e1-e8.	0.7	6
474	Association of True Positivity with Serum Prostate-Specific Antigen Levels and Other Clinical Factors in Indeterminate PSMA-RADS-3A Lesions Identified on 18F-DCFPyL PET/CT Scans. Tomography, 2022, 8, 2639-2647.	0.8	2
475	Unexpected Metastatic Localizations of Prostate Cancer Determined by ⁶⁸Ga PSMA PET/CT: Series of Four Cases. Molecular Imaging and Radionuclide Therapy, 2022, 31, 223-226.	0.3	0
476	PET/TC-PSMA en cÃ¡ncer de prÃ³stata: perfil de pacientes en la vida real. , 2022, 27, .		0
477	PET/TC 18F-PSMA para localizaciÃ³n anatÃ³mica de las recurrencias en el cÃ¡ncer de prÃ³stata. , 2022, 25, .		0
478	Detection of recurrence sites using 18F-fluorocholine PET/CT in prostate cancer patients with PSA failure. Prostate International, 2023, 11, 69-75.	1.2	2
479	PET/CT for Detection of Biochemical Recurrence Post Radical Prostatectomy. , 2022, , 43-46.		0

#	Article	IF	Citations
480	Phase III Study of¹⁸F-PSMA-1007 Versus¹⁸F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study. Journal of Nuclear Medicine, 2023, 64, 579-585.	2.8	12
481	68Ga-PSMA PET/CT in early relapsed prostate cancer patients after radical therapy. Scientific Reports, 2022, 12, .	1.6	2
483	Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nature Reviews Urology, 2023, 20, 23-47.	1.9	20
484	Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State. Diagnostics, 2022, 12, 3176.	1.3	6
486	PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1466-1486.	3.3	62
487	(18F)-PSMA-1007PET/CT in patients with biochemical recurrence after radical prostatectomy: Diagnostic performance and impact on treatment management. , 2023, 5, 100021.		1
488	Necessity of Pelvic Lymph Node Irradiation in Patients with Recurrent Prostate Cancer after Radical Prostatectomy in the PSMA PET/CT Era: A Narrative Review. Biomedicines, 2023, 11, 38.	1.4	1
489	ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer. Radiotherapy and Oncology, 2023, 183, 109544.	0.3	6
490	Addressing the need for more therapeutic options in neuroendocrine prostate cancer. Expert Review of Anticancer Therapy, 2023, 23, 177-185.	1.1	3
491	An analysis of PSMA-PET/CT-positive lymph node distribution and their coverage by different elective nodal radiation volumes in postoperative prostate cancer patients. Journal of Nuclear Medicine, 0, , jnumed.122.265159.	2.8	0
493	Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy. Cancers, 2023, 15, 1898.	1.7	2
494	A Retrospective Multicenter Analysis of the Incidence of Bone-Only Disease at PSMA PET/CT in Castration Resistant Prostate Cancer Patients. Cancers, 2023, 15, 2208.	1.7	2
496	Radiotherapy of patients with regional recurrence of prostate cancer after radical prostatectomy. , 2023, 13, 19-26.		0
515	Urologische Tumoren. , 2024, , 239-274.		0